The antibody-mediated targeted delivery of pro-inflammatory cytokines (such as IL-2, IL-12, TNF and interferon (IFN) γ) has resulted in impressive increase in the therapeutic index of these biopharmaceuticals, with striking curative activities in animal models of cancer [3,6,26,53]. Here, TNF is linked to cancer.